Daily BriefsMost Read

Most Read: Link REIT, Canon Inc, Ebos Group Ltd, Dai Nippon Printing, Kakao Pay, Citizen Watch, S.M.Entertainment Co, Tencent, Huitongda, Osstem Implant and more

In today’s briefing:

  • Big Link REIT (823 HK) Rights Offering
  • Canon ADR Cancellation – There May Be A Trade To Do
  • Index Rebalance & ETF Flow Recap: MSCI, CSI500, XIN9I, DTAC/TRUE, Newcrest, Adani, Korea Spinoffs
  • Dai Nippon Printing (7912) – Activism Results Going Forward Are Complicated
  • Kakao Pay (377300 KS): MSCI Inclusion (Finally!)
  • Absolutely GINORMOUS Citizen Watch (7762 JP) Buyback
  • HYBE’s Tender Offer of SM Entertainment: Closing the Price Gap
  • ECM Weekly (12th Feb 2023) – Hesai, Oasis, Mankind, Greatpower, Ruipeng, CATL, Nissan/Renault
  • Huitongda Lock-Up – US$1.1bn Pre-IPO Lock-Up Expiry. China-Based Funds at Least 40% Up
  • Osstem Implant: Founder Choi Changes CB Sale Terms to MBK-Unison & KCGI Agrees to Sell Its Shares

Big Link REIT (823 HK) Rights Offering

By Travis Lundy

  • After being halted this morning before the start of trade, post-close, Link REIT (823 HK) announced a fully-underwritten Rights Offering
  • The Rights Offering intends to raise HK$18.8bn issuing 1 Right for every 5 Shares held, at a subscription price of HK$44.20, a 26% discount to TERP. 
  • This will take an already under-levered REIT and add more capital to it. And there is going to be selling pressure at some point.

Canon ADR Cancellation – There May Be A Trade To Do

By Travis Lundy

  • Last week (on 10 February), Canon Inc (7751 JP) announced it intended to delist its ADRs from the NYSE.
  • Canon is the third Japanese company to do so in two months, after Eisai Co Ltd (4523 JP) announced in December and Olympus Corp (7733 JP) in January.
  • No related investment opportunity but there may be a trade to do.

Index Rebalance & ETF Flow Recap: MSCI, CSI500, XIN9I, DTAC/TRUE, Newcrest, Adani, Korea Spinoffs

By Brian Freitas

  • MSCI announced the changes to the GIMI on Friday as part of the February QCIR. MSCI also announced a review of the free float of the Adani Group companies.
  • FTSE will announce the changes to the All-World and All-Cap indices after the close of trading on Friday, 17 February. The same day is the S&P/ASX review cutoff for March.
  • Yet another weekly outflow for the IShares Edge MSCI Min Vol Emerging Markets ETF (EEMV US) taking the YTD outflow to over US$2.5bn.

Dai Nippon Printing (7912) – Activism Results Going Forward Are Complicated

By Travis Lundy

  • A little over two weeks ago, western media outlets reported “sources familiar with the matter” said Elliott Management had built a “significant” stake in Dai Nippon Printing (7912 JP)
  • DNP has been a “value name” for years. And years. Lots of cash, lots of real estate, and lots of cross-holdings. DNP had a plan to sell crossholdings, slowly.
  • DNP had planned a March 9 presentation of its new MTMP. Elliott, reportedly with a little less than 5%, wanted faster. A few weeks later, DNP has responded with faster. 

Kakao Pay (377300 KS): MSCI Inclusion (Finally!)

By Brian Freitas

  • MSCI will add Kakao Pay (377300 KS) to the MSCI Korea Index at the February QCIR. There are 7 trading days to implementation on 28 February.
  • Local institutions and foreign investors have been sellers in the last couple of weeks and retail investors have been buying to mop up the selling.
  • Cumulative excess volume indicates a fair amount of pre-positioning and we’d look to sell ahead of the passive MSCI buying.

Absolutely GINORMOUS Citizen Watch (7762 JP) Buyback

By Travis Lundy

  • Today, Citizen Watch (7762 JP) reported Q3 earnings, and a BIG buyback.
  • It is a VERY BIG BUYBACK at up to 75mm shares (25.61% of shares out), with an allocation of up to ¥40bn (which is ~22.1% at last price).
  • The buyback is to be executed over the next year. Buyback structure (undisclosed) matters and shareholder structure matters too. There is a big short. This could get really interesting.

HYBE’s Tender Offer of SM Entertainment: Closing the Price Gap

By Douglas Kim

  • We believe that there is a very high probability of a successful tender offer of 25% stake in SM Entertainment by HYBE. 
  • There is a 4.6% gap between the tender offer price and current price. There is a strong probability of this gap being closed in the next several weeks. 
  • There could also be an on-going interest by Kakao to try to take over the controlling interest in SM Entertainment but HYBE is not likely to give up control easily.

ECM Weekly (12th Feb 2023) – Hesai, Oasis, Mankind, Greatpower, Ruipeng, CATL, Nissan/Renault

By Sumeet Singh

  • Aequitas Research puts out a weekly update on the deals that were covered by the team recently along with updates for upcoming IPOs.
  • On the IPO front, Hesai Group (HSAI US) provided the first Asia linked listing for the year.
  • Things were quiet on the placement front owing to the annual earnings reporting season.

Huitongda Lock-Up – US$1.1bn Pre-IPO Lock-Up Expiry. China-Based Funds at Least 40% Up

By Clarence Chu

  • Huitongda (9878 HK) was listed on 18th Feb 2023, when it raised US$285m in its HK IPO. Its one-year lockup will expire on 17th February 2023.
  • Huitongda (HTD) is a commerce and service platform serving businesses in the lower-tier retail markets of China.
  • Coming up for one-year lockup expiry are HTD’s pre-IPO investors. With the exception of Alibaba and SOE backers, the bulk of HTD’s pre-IPO investors are still currently in the money.

Osstem Implant: Founder Choi Changes CB Sale Terms to MBK-Unison & KCGI Agrees to Sell Its Shares

By Douglas Kim

  • Due to the enormous controversy regarding Chairman Choi Gyu-Ok’s children exchange CB call options for BWs, the Choi family has decided to change and simplify this transaction structure.
  • Previously, MBK-Unison decided to acquire the call option on CB that Chairman Choi gave to his children. Under revised contract, MBK-Unison agreed to acquire the convertible bond itself.
  • We believe MBK-Unison consortium is getting a relative bargain in this deal and the valuation of Osstem Implant remain attractive (EV/EBITDA of 6.4x and P/E of 11.7x in 2024). 

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars